-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Biotech Patent
What OxyContin Tells Us About the Value of “Evergreening” and Patents
A few weeks ago, the FDA announced that they would not allow generic versions of older versions of OxyContin. The original formulation of OxyContin goes off patent today. The original formulation did not have “tamper-resistant qualities” that prevent people from “crushing, breaking, and dissolution using a variety of tools and solvents.” The article reports that the decision will keep Teva Pharmaceuticals and Impax Laboratories from making the older version which the FDA has determined is too dangerous Read More >
Patent and Tech Transfer Sessions at 2013 BIO International Convention
Patent and Technology Transfer sessions feature prominently at the 2013 BIO International Convention in Chicago from April 22-25, 2013. Topics cover developing patent and tech transfer issues in the U.S. and internationally. Many of the sessions provide Continuing Legal Education (CLE) and Registered Technology Transfer Professional (RTTP) credits. The Biotech Patenting and Technology Transfer Track sessions are below: Behind the Tech Transfer Headlines: What are You Missing? Headline-making news reports of multiyear, multimillion dollar strategic Read More >
Patently Biotech’s Top 5 Articles of 2012
2012 has been an eventful year for biotech IP issues. Below are the top 5 articles and from Patently Biotech in 2012. Click on the links to read the full articles. 1. The Real Reason Why Salk Refused to Patent the Polio Vaccine A guest writer in a recent article in the Wall Street Journal repeated the oft quoted Jonas Salk statement about his Polio vaccine: “There is no patent. Could you patent the sun?” Many use this statement Read More >
